Proceedings of the 5th Paris Hepatitis Conference. International Conference of the Management of Patients with Viral Hepatitis: Special Edition Hepatitis C: Liver International: Vol 32, No s1

I consent to Wiley Online Library’s Terms of Use and processing of my personal data as disclosed in Wiley’s Privacy Policy.I consent to my personal information being transferred outside of the People’s Republic of China as laid out in Wiley’s Privacy Policy.*(Optional) I consent to special offers, newsletter & promotions from Wiley. See Privacy Policy for more details.

Tools

Submit an article

Journal Metrics

Subscribe to this journal

Liver International

Journal list menu

Tools

Follow journal

Liver International: Volume 32, Issue s1

Special Issue:Proceedings of the 5th Paris Hepatitis Conference. International Conference of the Management of Patients with Viral Hepatitis: Special Edition Hepatitis C

Proceedings of the 5th Paris Hepatitis Conference. International Conference of the Management of Patients with Viral Hepatitis: Special Edition Hepatitis C

The publication of this supplement was supported by an unrestricted educational grant from Roche (founding partner), Merck and Janssen

Editorial

Towards the eradication of hepatitis C virus

Review Articles

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines

New targets for antiviral therapy of chronic hepatitis C

Telaprevir user's guide

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1

Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice

Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin

Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders

Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon and ribavirin: ‘Lead-in or no lead-in’?

Response-guided and -unguided treatment of chronic hepatitis C

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C

Treatment of chronic hepatitis C – are interferons really necessary?

Future treatment of patients with HCV cirrhosis

Hepatitis C virus treatment pre- and post-liver transplantation

Hepatitis C virus-human immunodeficiency virus coinfection

What's new in HCV genotype 2 treatment

Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies

The future for the treatment of genotype 4 chronic hepatitis C

Barriers to hepatitis C treatment

Tools

More from this journal

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Liver International

Journal list menu

Tools

Follow journal

Liver International: Volume 32, Issue s1

Special Issue:Proceedings of the 5th Paris Hepatitis Conference. International Conference of the Management of Patients with Viral Hepatitis: Special Edition Hepatitis C

Download PDFs

Proceedings of the 5th Paris Hepatitis Conference. International Conference of the Management of Patients with Viral Hepatitis: Special Edition Hepatitis C

The publication of this supplement was supported by an unrestricted educational grant from Roche (founding partner), Merck and Janssen

Editorial

Towards the eradication of hepatitis C virus

Review Articles

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines

New targets for antiviral therapy of chronic hepatitis C

Telaprevir user's guide

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1

Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice

Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin

Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders

Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon and ribavirin: ‘Lead-in or no lead-in’?

Response-guided and -unguided treatment of chronic hepatitis C

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C

Treatment of chronic hepatitis C – are interferons really necessary?

Future treatment of patients with HCV cirrhosis

Hepatitis C virus treatment pre- and post-liver transplantation

Hepatitis C virus-human immunodeficiency virus coinfection

What's new in HCV genotype 2 treatment

Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies

The future for the treatment of genotype 4 chronic hepatitis C

Barriers to hepatitis C treatment

Sign up for email alerts

Tools

More from this journal